The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Ten-year follow-up of the JCOG0203 trial on R-CHOP in FL patients

Nov 2, 2018

On 1 November 2018, Takashi Watanabefrom the National Cancer Center Hospital, Tokyo, Japan, and colleagues, published in The Lancet Haematology a 10-year follow-up outcome analysis of the  Japan Clinical Oncology Group(JCOG) 0203phase II/III trial ( NCT00147121).

During the JCOG0203trial, previously-untreated patients with indolent B-cell lymphoma, including follicular lymphoma (FL) from 44 centers around Japan, were randomly assigned to either rituximab (R), cyclophosphamide (C), doxorubicin (H), vincristine (O), and prednisone (P) (R-CHOP) every three weeks (R-CHOP-21) or every two weeks (R-CHOP-14), without R maintenance. The aim of this follow-up analysis was to assess progression-free survival (PFS), overall survival (OS), incidence of secondary malignancies, and incidence of histological transformation more than 10 years after the JCOG0203 trial.

Study design

  • N = 300 (2002–2007) previously-untreated advanced-stage indolent B-cell lymphoma patients were randomly assigned (1:1) to six cycles of R-CHOP-14 (every two weeks; n = 151) or R-CHOP-21 (every three weeks; n =149)
    • Same R-CHOP dosing between the two groups:
    • R: 375 mg/m 2on Day 1, C: 750 mg/m², H: 50 mg/m², and O: 1.4 mg/m² (capped at 2.0 mg) administered intravenously on Day 3. Oral P was administered once a day at 100 mg from Days 3–7 (for 5 days)
  • In the R-CHOP-14 and R-CHOP-21 groups, 81% (n = 123) and 84% (n = 125), respectively were patients with Grade 1–3a FL
  • Data updated in February 2017, 10 years after the last enrolment
  • Survival status and disease status was updated for all living participants except for 16 (5%) of them. One patient was not eligible for the survival analysis (n = 299)

Results

  • Median follow-up (range) across groups = 11.2 (1–12.7) years
  • R-CHOP-14
    • 10-year PFS = 39% (95% CI, 31–47)
    • 10-year OS = 85% (95% CI, 78–90)
    • Disease progression (PD) within two years of initial chemotherapy = 30% (n = 46/151)
  • R-CHOP-21
    • 10-year PFS = 33% (95% CI, 25–41)
    • 10-year OS = 81% (95% CI, 74–86)
    • Disease progression (PD) within two years of initial chemotherapy = 32% (n = 47/149)
  • The two groups did not significantly differ in their PFS or OS (HR = 0.89, [95% CI, 0.67–1.17] and HR = 0.87, [95% CI, 0.52–1.45], respectively)
  • Multivariable analysis revealed the following unfavorable parameters for PFS:
    • Male gender (HR =1.57, [95% CI,1.16–2.12])
  • Multivariable analysis revealed the following unfavorable predictor of OS:
    • Age ≥ 61 years (HR = 2.03, [95% CI,1.19–3.45])
    • Increased lactate dehydrogenase (LDH) (HR = 2.38, [95% CI,1.27–4.43])
  • In Grade 1–3a FL patients (n = 248):
    • 5-year PFS = 45% (95% CI, 39–51)
    • 8-year PFS = 39% (95% CI, 33–45)
    • 10-year PFS = 36% (95% CI, 30–42)
    • 5-year OS = 94% (95% CI, 91–97)
    • 8-year OS = 87% (95% CI, 82–91)
    • 10-year OS = 85% (95% CI, 79–89)

Safety & histological transformation

  • During the follow-up, histological transformation was:
    • diagnosed in 11% (n = 27/248) of patients with Grade 1–3a at enrolment
    • had a 3-year cumulative incidence of 2.4% (95% CI, 1.0–4.9)
    • had a 5-year cumulative incidence of 3.2% (95% CI, 1.5–6.0)
    • had an 8-year cumulative incidence of 8.5% (95% CI, 5.4–12.4)
    • had a 10-year cumulative incidence of 9.3% (95% CI, 6.1–13.4)
  • Three deaths (all in the R-CHOP-21 group) were reported due to late infections (pneumonia, interstitial pneumonitis, sepsis)
  • After 10 years, secondary malignancies were reported in 9% of the patients in either the R-CHOP-14 or R-CHOP-21 group, and lead to death, five patients in the R-CHOP-14 and four in the R-CHOP-21 group
  • Hematological malignancies developed in n = 3 patients in the R-CHOP-14 (1 acute lymphoblastic leukemia, 1 acute myeloid leukemia, and 1 myelodysplastic syndrome) and n = 7 in the R-CHOP-21 group (1 acute myeloid leukemia, 1 chronic myeloid leukemia, and 5 myelodysplastic syndromes)

This long-term follow-up of the JCOG0203 study provided an outcome analysis after more than ten years of the original trial. The investigators showed that approximately 30% of patients with advanced-stage FL receiving R-CHOP, did not progress after ten years without R maintenance. Both histological transformation and the incidence of secondary malignancies remained low after ten years for these patients (11% and 8.1%, respectively). These results indicate that R-CHOP continues to be a treatment option for newly-diagnosed indolent B-cell lymphoma patients but clinicians should be aware of the potential occurrence of late secondary malignancies.

  1. Watanabe T. et al.Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Lancet Haematology.November 01, 2018, 5(11):PE520-E531. DOI: 10.1016/S2352-3026(18)30155-8[Epub ahead of print].